Origins of Company
AlphaSniffer, LLC was founded in July 2003 by Dr. Misha Plam. In May 2008 the company name has been changed to BiOptix LLC. Dr. Plam is the former founder, CEO, President and Chairman of the Board of Sievers Instruments. Sievers Instruments successfully commercialized the Total Organic Carbon Analyzer, which became a key component that pharmaceutical and semi-conductor companies use to monitor organic carbon contamination present in their water supply. The device also flew aboard Russian space station Mir and is currently deployed on the International Space Station. Dr. Plam subsequently sold Sievers to Ionics (now GE) for $21MM. AlphaSniffer is located in Boulder, Colorado where significant talent exists and can be recruited to drive the company’s developmental progress toward profitability.
AlphaSniffer is in the R&D stage and has no revenues other than from SBIR grants. It has received over $500K in SBIR grants over the past 4 years. AlphaSniffer is currently structured as a limited liability company (LLC) with a syndicate of investors who provided significant financing for product development and company operations. The company intends to convert into a C-corporation upon closure of its series A venture capital round.
Mission Statement
AlphaSniffer’s mission is to profitably develop its novel and proprietary Common Path Interferometer (CPI) instrument platform for detection of molecular interactions so as to enhance human security, health and welfare. AlphaSniffer’s core competency is the development of analytical devices, particularly those that rely upon optoelectronics. The founders and board of directors have significant experience delivering commercial products such as the TOC analyzer to market, from idea inception through revenue generation and sale of their companies.
Operational core competencies include:
Optoelectronic engineering
Signal processing
Biochemistry and bioarray engineering
Protocol development
Engineering for manufacturability
AlphaSniffer seeks to revolutionize the molecular interaction markets with its groundbreaking label free technology that vastly simplifies the 20+ year old immunoassay methods that currently dominate the market.
|